Business Context and Reporting Period
This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders for Rocket Pharmaceuticals, Inc., held on June 13, 2022. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Market under the symbol RCKT.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Stockholders representing approximately 86.03% of eligible shares (55,510,402 shares) participated in the meeting. Three proposals were voted upon:
- Proposal One (Election of Directors): Stockholders approved the election of all nine nominees to the Board of Directors. Vote counts varied by nominee, with "Votes For" ranging from approximately 36.1 million to 48.2 million.
- Proposal Two (Ratification of Accounting Firm): Stockholders ratified the appointment of EisnerAmper LLP as the independent registered accounting firm for the fiscal year ending December 31, 2022. The vote was 55,475,923 For, 30,029 Against, and 4,450 Abstentions.
- Proposal Three (Executive Compensation): Stockholders approved the non-binding advisory vote on executive compensation. The vote was 42,160,877 For, 6,240,249 Against, and 7,977 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. It is strictly a disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the full list of elected directors and their tenure terms in the company's proxy statement.
- Confirm the specific compensation details for Named Executive Officers referenced in the advisory vote.
- Review the most recent 10-K or 10-Q filings for actual financial performance metrics, as this 8-K contains none.
- Note that EisnerAmper LLP is the confirmed auditor for the fiscal year ending December 31, 2022.